Susan B. Meister Child Health Evaluation and Research Center, Department of Pediatrics, University of Michigan Medical School, Ann Arbor, Michigan; Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor, Michigan.
Department of Markets, Public Policy & Law, Institute for Health System Innovation and Policy, Questrom School of Business, Boston University, Boston, Massachusetts.
Am J Prev Med. 2021 Apr;60(4):537-541. doi: 10.1016/j.amepre.2020.11.004. Epub 2021 Feb 18.
Although many Medicare Advantage plans have waived cost sharing for COVID-19 hospitalizations, these waivers are voluntary and may be temporary. To estimate the magnitude of potential patient cost sharing if waivers are not implemented or are allowed to expire, this study assesses the level and predictors of out-of-pocket spending for influenza hospitalizations in 2018 among elderly Medicare Advantage patients.
Using the Optum De-Identified Clinformatics DataMart, investigators identified Medicare Advantage patients aged ≥65 years hospitalized for influenza in 2018. For each hospitalization, out-of-pocket spending was calculated by summing deductibles, coinsurance, and copays. The mean out-of-pocket spending and the proportion of hospitalizations with out-of-pocket spending exceeding $2,500 were calculated. A 1-part generalized linear model with a log link and Poisson variance function was fitted to model out-of-pocket spending as a function of patient demographic characteristics, plan type, and hospitalization characteristics. Coefficients were converted to absolute changes in out-of-pocket spending by calculating average marginal effects.
Among 14,278 influenza hospitalizations, the mean out-of-pocket spending was $987 (SD=$799). Out-of-pocket spending exceeded $2,500 for 3.0% of hospitalizations. The factors associated with higher out-of-pocket spending included intensive care use, greater length of stay, and enrollment in a preferred provider organization plan (average marginal effect=$634, 95% CI=$631, $636) compared with enrollment in an HMO plan.
In this analysis of elderly Medicare Advantage patients, the mean out-of-pocket spending for influenza hospitalizations was almost $1,000. Federal policymakers should consider passing legislation mandating insurers to eliminate cost sharing for COVID-19 hospitalizations. Insurers with existing cost-sharing waivers should consider extending them indefinitely, and those without such waivers should consider implementing them immediately.
尽管许多医疗保险优势计划已免除 COVID-19 住院治疗的自付费用,但这些豁免是自愿的,可能是暂时的。为了评估如果不实施或允许豁免过期,潜在患者自付费用的规模,本研究评估了 2018 年老年医疗保险优势患者流感住院的自付水平和预测因素。
研究人员使用 Optum De-Identified Clinformatics DataMart,确定了 2018 年因流感住院的≥65 岁医疗保险优势患者。对于每次住院,通过汇总免赔额、共付额和 copays 来计算自付费用。计算了自付费用的平均值和自付费用超过 2500 美元的住院比例。使用具有对数链接和泊松方差函数的 1 部分广义线性模型拟合模型,将自付费用作为患者人口统计学特征、计划类型和住院特征的函数进行建模。通过计算平均边际效应,将系数转换为自付费用的绝对变化。
在 14278 例流感住院中,平均自付费用为 987 美元(SD=799 美元)。超过 2500 美元的自付费用占住院的 3.0%。与 HMO 计划相比,与更高自付费用相关的因素包括重症监护使用、更长的住院时间和参加首选供应商组织计划(平均边际效应=634 美元,95%CI=631 美元,636 美元)。
在这项对老年医疗保险优势患者的分析中,流感住院的平均自付费用接近 1000 美元。联邦政策制定者应考虑通过立法,要求保险公司免除 COVID-19 住院治疗的自付费用。有现有自付费用豁免的保险公司应考虑将其无限期延长,而没有此类豁免的保险公司应考虑立即实施。